Do analysts rate TLRY or CRDL?

Tilray Brands presently has a consensus target price of C$13.30, indicating a potential upside of 110.78%. Given Tilray Brands' stronger consensus rating and higher possible upside, equities research analysts clearly believe Tilray Brands is more favorable than Cardiol Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tilray Brands 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, CMED or CRDL?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CanniMed Therapeutics N/A N/A N/A N/A N/A Cardiol Therapeutics N/A N/A -C$42.93M -C$0.39 N/A

Is CMED or CRDL more profitable?

CanniMed Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets CanniMed Therapeutics N/A N/A N/A Cardiol Therapeutics N/A -229.16% -54.15%

Do analysts rate WEED or CRDL?

Canopy Growth currently has a consensus target price of C$1.88, indicating a potential upside of 35.87%. Given Canopy Growth's stronger consensus rating and higher possible upside, equities research analysts plainly believe Canopy Growth is more favorable than Cardiol Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend CRDL or FRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Fennec Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00

Do analysts recommend CPH or CRDL?

Cipher Pharmaceuticals presently has a consensus target price of C$17.00, indicating a potential upside of 21.08%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Cardiol Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cipher Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Cardiol Therapeutics (CRDL) Competitors

C$2.32 -0.10 (-4.13%)

As of 11:59 AM Eastern

Compare

CRDL vs. TLRY, CMED, WEED, FRX, and CPH

Should you buy Cardiol Therapeutics stock or one of its competitors? Cardiol Therapeutics's main competitors and comparable companies include Tilray Brands (TLRY), CanniMed Therapeutics (CMED), Canopy Growth (WEED), Fennec Pharmaceuticals (FRX), and Cipher Pharmaceuticals (CPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cardiol Therapeutics compare to Tilray Brands?

Tilray Brands (TSE:TLRY) and Cardiol Therapeutics (TSE:CRDL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

In the previous week, Tilray Brands had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Tilray Brands and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.38 beat Tilray Brands' score of -0.09 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tilray Brands	Neutral
Cardiol Therapeutics	Positive

4.6% of Tilray Brands shares are held by institutional investors. Comparatively, 0.0% of Cardiol Therapeutics shares are held by institutional investors. 0.7% of Tilray Brands shares are held by insiders. Comparatively, 4.6% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cardiol Therapeutics has lower revenue, but higher earnings than Tilray Brands. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	C$915.45M	0.94	-C$183.24M	-C$1.09	N/A
Cardiol Therapeutics	N/A	N/A	-C$42.93M	-C$0.39	N/A

Tilray Brands has a beta of 2.949831, indicating that its stock price is 195% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.270267, indicating that its stock price is 73% less volatile than the broader market.

Tilray Brands presently has a consensus target price of C$13.30, indicating a potential upside of 110.78%. Given Tilray Brands' stronger consensus rating and higher possible upside, equities research analysts clearly believe Tilray Brands is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardiol Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cardiol Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -15.22%. Tilray Brands' return on equity of -8.85% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-15.22%	-8.85%	-1.41%
Cardiol Therapeutics	N/A	-229.16%	-54.15%

Summary

Tilray Brands beats Cardiol Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Cardiol Therapeutics compare to CanniMed Therapeutics?

CanniMed Therapeutics (TSE:CMED) and Cardiol Therapeutics (TSE:CRDL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

0.0% of Cardiol Therapeutics shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CanniMed Therapeutics' return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CanniMed Therapeutics	N/A	N/A	N/A
Cardiol Therapeutics	N/A	-229.16%	-54.15%

In the previous week, Cardiol Therapeutics had 1 more articles in the media than CanniMed Therapeutics. MarketBeat recorded 1 mentions for Cardiol Therapeutics and 0 mentions for CanniMed Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.38 beat CanniMed Therapeutics' score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CanniMed Therapeutics	Neutral
Cardiol Therapeutics	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CanniMed Therapeutics	N/A	N/A	N/A	N/A	N/A
Cardiol Therapeutics	N/A	N/A	-C$42.93M	-C$0.39	N/A

Summary

Cardiol Therapeutics beats CanniMed Therapeutics on 4 of the 6 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Canopy Growth?

Canopy Growth (TSE:WEED) and Cardiol Therapeutics (TSE:CRDL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Canopy Growth currently has a consensus target price of C$1.88, indicating a potential upside of 35.87%. Given Canopy Growth's stronger consensus rating and higher possible upside, equities research analysts plainly believe Canopy Growth is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cardiol Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

4.1% of Canopy Growth shares are held by institutional investors. Comparatively, 0.0% of Cardiol Therapeutics shares are held by institutional investors. 0.2% of Canopy Growth shares are held by company insiders. Comparatively, 4.6% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Canopy Growth has a beta of 1.382001, suggesting that its stock price is 38% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.270267, suggesting that its stock price is 73% less volatile than the broader market.

Cardiol Therapeutics has lower revenue, but higher earnings than Canopy Growth. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	C$293.63M	1.98	-C$1.05B	-C$0.67	N/A
Cardiol Therapeutics	N/A	N/A	-C$42.93M	-C$0.39	N/A

In the previous week, Canopy Growth had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Canopy Growth and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.38 beat Canopy Growth's score of 0.78 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Canopy Growth	Positive
Cardiol Therapeutics	Positive

Cardiol Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -73.95%. Canopy Growth's return on equity of -29.85% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-73.95%	-29.85%	-3.83%
Cardiol Therapeutics	N/A	-229.16%	-54.15%

Summary

Canopy Growth beats Cardiol Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Fennec Pharmaceuticals?

Cardiol Therapeutics (TSE:CRDL) and Fennec Pharmaceuticals (TSE:FRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

Fennec Pharmaceuticals has higher revenue and earnings than Cardiol Therapeutics. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-C$42.93M	-C$0.39	N/A
Fennec Pharmaceuticals	C$51.00M	11.59	-C$800.44K	-C$0.29	N/A

0.0% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 14.5% of Fennec Pharmaceuticals shares are held by institutional investors. 4.6% of Cardiol Therapeutics shares are held by insiders. Comparatively, 16.2% of Fennec Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cardiol Therapeutics has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -6.21%. Fennec Pharmaceuticals' return on equity of -13.34% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.16%	-54.15%
Fennec Pharmaceuticals	-6.21%	-13.34%	8.88%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Fennec Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Cardiol Therapeutics has a beta of 0.270267, indicating that its share price is 73% less volatile than the broader market. Comparatively, Fennec Pharmaceuticals has a beta of 3.548856, indicating that its share price is 255% more volatile than the broader market.

In the previous week, Fennec Pharmaceuticals had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Fennec Pharmaceuticals and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.38 beat Fennec Pharmaceuticals' score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cardiol Therapeutics	Positive
Fennec Pharmaceuticals	Neutral

Summary

Fennec Pharmaceuticals beats Cardiol Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Cipher Pharmaceuticals?

Cipher Pharmaceuticals (TSE:CPH) and Cardiol Therapeutics (TSE:CRDL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Cipher Pharmaceuticals presently has a consensus target price of C$17.00, indicating a potential upside of 21.08%. Given Cipher Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Cipher Pharmaceuticals is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardiol Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cipher Pharmaceuticals has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	7.00	C$11.41M	C$1.19	11.80
Cardiol Therapeutics	N/A	N/A	-C$42.93M	-C$0.39	N/A

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 2 mentions for Cipher Pharmaceuticals and 1 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of 1.38 beat Cipher Pharmaceuticals' score of 1.23 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cipher Pharmaceuticals	Positive
Cardiol Therapeutics	Positive

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Cardiol Therapeutics shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Comparatively, 4.6% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Cipher Pharmaceuticals has a beta of 1.153789, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.270267, suggesting that its stock price is 73% less volatile than the broader market.

Cipher Pharmaceuticals has a net margin of 58.81% compared to Cardiol Therapeutics' net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 22.74% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	58.81%	22.74%	7.90%
Cardiol Therapeutics	N/A	-229.16%	-54.15%

Summary

Cipher Pharmaceuticals beats Cardiol Therapeutics on 13 of the 14 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDL vs. The Competition

Export

Metric	Cardiol Therapeutics	Pharmaceuticals Industry	Healthcare Sector	TSE Exchange
Market Cap	C$267.43M	C$11.72B	C$6.98B	C$12.53B
Dividend Yield	N/A	2.70%	2.58%	6.20%
P/E Ratio	-5.95	783.86	269.56	30.69
Price / Sales	N/A	748.12	596.34	9.75
Price / Cash	0.98	67.45	70.53	82.29
Price / Book	10.45	10.74	13.02	4.63
Net Income	-C$42.93M	C$2.78B	C$3.45B	C$299.09M
7 Day Performance	16.58%	-0.29%	0.69%	0.75%
1 Month Performance	42.33%	-0.17%	1.32%	3.71%
1 Year Performance	25.41%	160.95%	66.86%	35.85%

Cardiol Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDL Cardiol Therapeutics	N/A	C$2.32 -4.1%	N/A	+58.2%	C$267.43M	N/A	N/A	20	Positive News Earnings Report Gap Down
TLRY Tilray Brands	1.3283 of 5 stars	C$6.36 +1.8%	C$13.30 +109.1%	-61.9%	C$866.26M	C$915.45M	N/A	2,650
CMED CanniMed Therapeutics	N/A	N/A	N/A	N/A	C$668.44M	N/A	N/A	147,000
WEED Canopy Growth	2.4669 of 5 stars	C$1.37 +3.0%	C$1.88 +36.9%	-37.9%	C$578.35M	C$284.60M	N/A	2,700	Earnings Report
FRX Fennec Pharmaceuticals	0.0454 of 5 stars	C$16.02 +6.8%	N/A	+36.0%	C$556.49M	C$51.00M	N/A	10	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:CRDL) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. TLRY, CMED, WEED, FRX, and CPH

How does Cardiol Therapeutics compare to Tilray Brands?

Summary

How does Cardiol Therapeutics compare to CanniMed Therapeutics?

Summary

How does Cardiol Therapeutics compare to Canopy Growth?

Summary

How does Cardiol Therapeutics compare to Fennec Pharmaceuticals?

Summary

How does Cardiol Therapeutics compare to Cipher Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. TLRY, CMED, WEED, FRX, and CPH

How does Cardiol Therapeutics compare to Tilray Brands?

Does the media favor TLRY or CRDL?

Do insiders and institutionals believe in TLRY or CRDL?

Which has preferable valuation and earnings, TLRY or CRDL?

Which has more risk and volatility, TLRY or CRDL?

Do analysts rate TLRY or CRDL?

Is TLRY or CRDL more profitable?

Summary

How does Cardiol Therapeutics compare to CanniMed Therapeutics?

Do insiders & institutionals believe in CMED or CRDL?

Is CMED or CRDL more profitable?

Does the media refer more to CMED or CRDL?

Which has higher valuation and earnings, CMED or CRDL?

Summary

How does Cardiol Therapeutics compare to Canopy Growth?

Do analysts rate WEED or CRDL?

Do institutionals & insiders believe in WEED or CRDL?

Which has more risk & volatility, WEED or CRDL?

Which has stronger earnings and valuation, WEED or CRDL?

Does the media prefer WEED or CRDL?

Is WEED or CRDL more profitable?

Summary

How does Cardiol Therapeutics compare to Fennec Pharmaceuticals?

Which has stronger valuation & earnings, CRDL or FRX?

Do insiders and institutionals hold more shares of CRDL or FRX?

Is CRDL or FRX more profitable?

Do analysts recommend CRDL or FRX?

Which has more risk and volatility, CRDL or FRX?

Does the media favor CRDL or FRX?

Summary

How does Cardiol Therapeutics compare to Cipher Pharmaceuticals?

Do analysts recommend CPH or CRDL?

Which has better valuation and earnings, CPH or CRDL?

Does the media prefer CPH or CRDL?

Do institutionals and insiders believe in CPH or CRDL?

Which has more volatility & risk, CPH or CRDL?

Is CPH or CRDL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools